Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation
- 1 November 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4062-4070
- https://doi.org/10.1128/aac.00148-07
Abstract
In this study, we analyzed the mechanisms of multiresistance for 22 clinical multiresistant and clonally different Pseudomonas aeruginosa strains from Germany. Twelve and 10 strains originated from cystic fibrosis (CF) and non-CF patients, respectively. Overproduction of the efflux systems MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM was studied. Furthermore, loss of OprD, alterations in type II topoisomerases, AmpC overproduction, and the presence of 25 acquired resistance determinants were investigated. The presence of a hypermutation phenotype was also taken into account. Besides modifications in GyrA (91%), the most frequent mechanisms of resistance were MexXY-OprM overproduction (82%), OprD loss (82%), and AmpC overproduction (73%). Clear differences between strains from CF and non-CF patients were found: numerous genes coding for aminoglycoside-modifying enzymes and located, partially in combination with beta-lactamase genes, in class 1 integrons were found only in strains from non-CF patients. Furthermore, multiple modifications in type II topoisomerases conferring high quinolone resistance levels and overexpression of MexAB-OprM were exclusively detected in multiresistant strains from non-CF patients. Correlations of the detected phenotypes and resistance mechanisms revealed a great impact of efflux pump overproduction on multiresistance in P. aeruginosa. Confirming previous studies, we found that additional, unknown chromosomally mediated resistance mechanisms remain to be determined. In our study, 11 out of 12 strains and 3 out of 10 strains from CF patients and non-CF patients, respectively, were hypermutable. This extremely high proportion of mutator strains should be taken into consideration for the treatment of multiresistant P. aeruginosa.Keywords
This publication has 49 references indexed in Scilit:
- Stepwise Upregulation of thePseudomonas aeruginosaChromosomal Cephalosporinase Conferring High-Level β-Lactam Resistance Involves Three AmpD HomologuesAntimicrobial Agents and Chemotherapy, 2006
- Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- AmpC and OprD Are Not Involved in the Mechanism of Imipenem Hypersusceptibility among Pseudomonas aeruginosa Isolates Overexpressing the mexCD - oprJ Efflux PumpAntimicrobial Agents and Chemotherapy, 2005
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005
- Detection of VIM-2 Metallo-β-Lactamase in Pseudomonas aeruginosa from GermanyAntimicrobial Agents and Chemotherapy, 2005
- Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosaClinical Microbiology & Infection, 2004
- Lack of Association between Hypermutation and Antibiotic Resistance Development inPseudomonas aeruginosaIsolates from Intensive Care Unit PatientsAntimicrobial Agents and Chemotherapy, 2004
- Emergence of the Extended-Spectrum β-Lactamase GES-1 in a Pseudomonas aeruginosa Strain from Brazil: Report from the SENTRY Antimicrobial Surveillance ProgramAntimicrobial Agents and Chemotherapy, 2004
- Nosocomial Outbreak of Extended-Spectrum β-Lactamase SHV-5-Producing Isolates ofPseudomonas aeruginosain Athens, GreeceAntimicrobial Agents and Chemotherapy, 2004
- Contribution of the MexXY Multidrug Transporter to Aminoglycoside Resistance in Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2003